Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

5-(2,5-bis(4-chloro-2-isopropylphenyl)thiophen-3-yl)-1h-tetrazole for the topical treatment of bacterial infections

A technology of cumene and thiophene, which can be used as a dermatologically acceptable carrier to eliminate pathogenic bacteria in diabetic ulcers, in the field of cellulitis drugs, and can solve problems such as multidrug resistance

Pending Publication Date: 2020-08-11
DENOVAMED
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Unfortunately, currently available topical antibiotics are often ineffective due to their own physicochemical properties that prevent them from penetrating deep into the skin
Furthermore, multidrug resistance (MDR) has been demonstrated within DFIs, presenting challenges in designing appropriate therapies

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • 5-(2,5-bis(4-chloro-2-isopropylphenyl)thiophen-3-yl)-1h-tetrazole for the topical treatment of bacterial infections
  • 5-(2,5-bis(4-chloro-2-isopropylphenyl)thiophen-3-yl)-1h-tetrazole for the topical treatment of bacterial infections
  • 5-(2,5-bis(4-chloro-2-isopropylphenyl)thiophen-3-yl)-1h-tetrazole for the topical treatment of bacterial infections

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0066] Example 1 - Synthesis of 5-(2,5-bis(4-chloro-2-isopropylphenyl)thiophen-3-yl)-1H-tetrazole

[0067] Refer to the following chemical schemes:

[0068]

[0069] Bromonitrile 2 (1.0 g, 3.7 mmol), isopropylphenyl borate 1 (2.31 g, 8.2 mmol, 2.2 equivalents) and Pd (PPh 3 ) 4 (0.22 g, 0.19 mmol, 0.05 equiv) was added to a round bottom flask and vacuum was applied for 3 seconds and flushed with argon 3 times. To this mixture was added 2M aqueous sodium carbonate solution (9.4ml, 18.8mmol, 5eq) and 20ml of dioxane. The reaction was stirred overnight at 95 °C, then quenched with water. The dark mixture was extracted with ethyl acetate (2 x 20ml), dried over anhydrous sodium sulfate, filtered and concentrated by rotary evaporation. Thiobenzonitrile 3 (1.4 g, 90%) was obtained by flash column chromatography (25% DCM in hexane).

[0070] Thiobenzonitrile 3 (1.0g, 2.4mmol), sodium azide (0.39g, 6.0mmol, 2.5eq) and zinc bromide (1.36g, 6.0mmol, 2.5eq) were mixed with 20ml of...

Embodiment 2

[0072] Example 2 (prophetic)

[0073] Azide-free Synthesis of 5-(2,5-bis(4-chloro-2-isopropylphenyl)thiophen-3-yl)-1H-tetrazole

[0074] 5-(2,5-Bis(4-chloro-2-isopropylphenyl)thiophen-3-yl)-1H-tetrazole can also be prepared by protecting the tetrazole to give a mixture of N-protected tetrazoles . This step is followed by bromination to give the N-protected 5-bromotetrazole mixture, followed by palladium cross-coupling using thiophen-3-ylboronic acid. The resulting product was then brominated at the 2- and 5-positions of thiophene, followed by palladium cross-coupling using (4-chloro-2-isopropylphenyl)boronic acid. Deprotection of the N-protected tetrazole moiety decomposes the mixture into single products. Deprotection may be combined with or subsequently introduced into a pharmaceutically acceptable salt moiety using methods known in the art. A possible synthesis is given in the following scheme, where the nitrogen protecting group is benzyl:

[0075]

[0076]

Embodiment 3-

[0078] Preparation of a pharmaceutical composition comprising 5-(2,5-bis(4-chloro-2-isopropylphenyl)thiophen-3-yl)-1H-tetrazole and a dermatologically acceptable carrier

[0079] Compounds were formulated by dissolving 50 mg of compound in 50 μl of 100% DMSO, then gradually added and mixed into 5 ml of Glaxal matrix (WellSpring Pharmaceutical Canada Corp., Oakville, Canada) at a final concentration of 1% (w / v) compound and 1% (v / v) DMSO.

[0080] biological data

[0081] Minimum Inhibitory Concentration (MIC)

[0082] Using a broth microdilution assay according to Clinical Laboratory Standards Institute (CSLI) guidelines, we tested 5-(2,5-bis(4-chloro-2-isopropylphenyl)thiophen-3-yl)- 1H-tetrazole ("test sample" in the table below), established MICs against a variety of MDR bacteria and indicated associations with methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant enterococci ( VRE) and substantial activity of Streptococcus species. Antimicrobial susc...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Mic valueaaaaaaaaaa
Login to View More

Abstract

A compound 5-(2,5-bis(4-chloro-2-isopropylphenyl)thiophen-3-yl)-1H-tetrazole, methods for the manufacture of said compound, topical compositions comprising said compound and methods of use thereof inthe topical treatment of infections caused by pathogenic bacteria as a wound site.

Description

[0001] Cross References to Related Applications [0002] This application claims priority to U.S. Provisional Patent Application No. 62 / 597,159, entitled "Topical Treatment of Infections," filed December 11, 2017, the contents of which are incorporated herein by reference. Background technique [0003] Diabetes is a serious disease that affects more than 415 million people worldwide and the incidence of the disease is projected to rise to more than 642 million by 2035 (International Diabetes Federation, 2016). People with diabetes can experience a number of serious complications, including decreased peripheral blood flow. Reduced blood flow to the extremities can cause episodes of peripheral neuropathy, the degeneration of peripheral nerves. Affecting up to 50% of people with diabetes, peripheral neuropathy is typically characterized by tingling, numbness and inability to feel pain in extremities, which can lead to infection developing into a diabetic ulcer (so-called "diabe...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07D409/04A61K31/40A61K8/49A61P31/04A61Q19/06
CPCA61K8/49A61Q19/06C07D409/04A61P31/04A61Q17/005A61K31/41A61P17/02
Inventor 吴帆克里斯多夫·R·麦克马斯特唐纳德·F·韦弗
Owner DENOVAMED
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com